---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-100522"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2022-04-08T23:59:59+00:00"
generated_at: "2026-06-26T08:30:47.290579+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Frequency Therapeutics cuts 30% of workforce, appoints new CFO

## Summary
- Workforce reduction of ~30% to focus capital on FX-322, FX-345, and MS program.
- Estimated $1.2M in future cash severance costs; majority implemented, remainder by July 31, 2022.
- Richard M. Mitrano appointed principal financial officer, succeeding Peter P. Pfreundschuh.
- Mitrano previously Vice President of Finance and Operations since July 2016.

## SEC filing metadata
- accession: 0001193125-22-100522
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2022-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/0001193125-22-100522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/d348577d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-100522
- JSON: https://secwatch.observer/filing/0001193125-22-100522.json
- Plain text: https://secwatch.observer/filing/0001193125-22-100522.txt

## Key facts
- Executive change
  Peter P. Pfreundschuh departed as Chief Financial Officer at Korro Bio, Inc..
  - Action: succeeded
  - Role: Chief Financial Officer
  source text: On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer, succeeding Peter P. Pfreundschuh, the Company’s former Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/0001193125-22-100522-index.htm
- Executive change
  Richard M. Mitrano was appointed as principal financial officer and principal accounting officer at Korro Bio, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/0001193125-22-100522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.